vimarsana.com

Page 73 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India helping to address issue of vaccine equity, says top U N Women official Anita Bhatia

Assistant-Secretary-General & Deputy Executive Director of U.N. Women Anita Bhatia. Photo: Twitter/@abhatiaunwomen   “India is a leader. I’m so proud of my country for this because there are so many people in need of vaccines,” Ms. Bhatia told PTI in an interview. Lauding India for its vaccine leadership, a top U.N. Women official has said the country was directly helping to address the issue of vaccine equity while rich nations were “cutting side deals” with pharmaceutical giants to buy more vaccines than they actually need. India is called the pharmacy of the world during the COVID-19 pandemic with its vast experience and deep knowledge in medicine. The country is one of the world’s biggest drug-makers and an increasing number of countries have already approached it for procuring coronavirus vaccines.

Covaxin safe, induces immune response with no severe effects: Lancet | India News

Covaxin has better reactogenicity and safety outcomes in phase II, claims study

Covaxin demand grows among Indians after efficacy results

Covaxin demand grows among Indians after efficacy results ​ By IANS | Published on ​ Tue, Mar 9 2021 18:12 IST | ​ 0 Views Covaxin generated excellent safety data, says Bharat Biotech. Image Source: IANS News New Delhi, March 9 : As India s vaccination drive against Covid-19 gathers momentum, the clouds of initial hesitancy about receiving Covaxin, developed by Hyderabad-based Bharat Biotech, has now cleared, raising demand and acceptability of the country s first indigenous vaccine against the disease. While a major boost to the vaccine s acceptability came after Prime Minister Narendra Modi received the first dose of the vaccine earlier this month, the publication of efficacy results gave the vaccine another shot in the arm.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.